Introduction {#Sec1}
============

Corticotroph adenomas represent approximately 5--10% of all pituitary adenomas (PAs) \[[@CR1], [@CR2]\]. Their most common clinical manifestation is Cushing's disease that is caused by hormonally active, adrenocorticotropin (ACTH) secreting tumors. ACTH-producing pituitary adenomas are the most common non-iatrogenic cause of Cushing's syndrome (hypercortisolemia from any source) and account for an estimated 70% of all cases \[[@CR3], [@CR4]\]. In 85% of the cases of Cushing's disease, the tumor is a well-demarcated microadenoma \[[@CR5]\]. A minority of corticotroph adenomas (7--9%) are hormonally silent and usually present as macroadenomas causing mass effect, including headache and vision defects \[[@CR6]\]. When compared to other types of silent adenomas (mainly null cell and gonadotroph adenomas), silent corticotroph adenomas (SCAs) are considered to recur earlier and more frequently \[[@CR7]--[@CR9]\]. Based on their morphology observed using electron microscopy and low molecular weight keratin (LMWK)-CAM5.2 immunohistochemical staining, corticotroph adenomas are divided into densely (DG-ACTH) and sparsely (SG-ACTH) granulated that correspond to subtype I and subtype II silent corticotroph adenomas, respectively \[[@CR10]\] (Fig. [1](#Fig1){ref-type="fig"}a, b). Another variant of corticotroph pituitary adenomas is Crooke's cell adenoma (CCA). Crooke's cells are corticotrophs that, in the setting of glucocorticoid excess (regardless of its etiology), undergo massive accumulation of perinuclear cytokeratin filaments, giving their cytoplasm a distinct hyalinized appearance on hematoxylin and eosin stain (Fig. [1](#Fig1){ref-type="fig"}c, d). The hyaline change is assumed to represent a response of normal, non-neoplastic corticotroph cells to elevated glucocorticoids level and is generally not observed in adenoma cells except Crooke's cell adenoma \[[@CR6], [@CR11], [@CR12]\]. This type of adenoma is considered to be innately aggressive, invasive, associated with significant morbidity and is prone to recurrence rates as high as 60% \[[@CR12], [@CR13]\].

Fig. 1Pituitary corticotroph adenomas. **a** Ultrastructural features of densely granulated corticotroph adenoma: well-developed organelles, numerous, variable in shape, and electron dense secretory granules. Original magnification ×7400. **b** Electron microscopy of sparsely granulated corticotroph adenoma: small and scanty secretory granules. Original magnification ×9700. **c** H&E staining of Crooke's cell adenoma (×200). **d** Ultrastructural features of Crooke's cell adenoma: excessive accumulation of perinuclear cytokeratin filaments. Original magnification ×9700

Predicting the behavior of pituitary adenomas in terms of invasiveness, aggressiveness, recurrence and postoperative patient outcome requires tumor markers that correlate accurately with the mentioned features. The 2004 WHO classification of endocrine tumors besides typical benign pituitary adenomas and pituitary carcinomas distinguishes a group of tumors exhibiting 'borderline or uncertain behavior' classified as atypical adenomas \[[@CR14], [@CR15]\]. Atypical adenomas are characterized by elevated mitotic index, Ki-67 labeling index (LI) \> 3% and extensive nuclear reactivity for p53 \[[@CR15]\]. In addition, the expression of MGMT (*O*-6-methylguanine-DNA methyltransferase) can be assessed in order to predict PA's sensitivity to temozolomide, an alkylating chemotherapeutic \[[@CR13]\].

Despite their widespread use and recommendation by 2004 WHO classification, the usefulness of Ki-67 index and p53 immunopositivity as reliable markers of pituitary tumor biology remains controversial. Some authors suggest that these markers have no superiority over the mentioned detailed histological typing of pituitary adenomas \[[@CR16]\]. Other biomarkers of PA aggressiveness include fibroblast growth factor receptor 4 (FGFR 4), matrix metalloproteinases (MMPs), presence of growth hormone receptor mutations, loss of chromosome arm 11p and/or 11q and pituitary tumor transforming gene 1 (PTTG1) overexpression \[[@CR17]\]. Most recently, Coli et al. have reported a significantly increased expression of minichromosome maintenance complex component 7 (MCM7) in invasive ACTH-producing PAs \[[@CR18]\] and proposed MCM7 labeling index as a prognostic marker of clinical outcome in PA patients.

MicroRNAs (miRNAs) are known to play a crucial role in the pathogenesis of cancer and recently they are emerging as novel neoplastic biomarkers \[[@CR19]\]. They are short (18--24 nucleotides in length), noncoding RNA molecules that regulate gene expression at the post-transcriptional level. MiRNAs influence mRNA stability and translation by binding to regulatory sites located primarily in the 3′ untranslated region (UTR) of the targeted transcripts \[[@CR20], [@CR21]\]. Recent studies have shown that miR-106b\~25 cluster, consisting of highly conserved miRNAs: miR-25, miR-93 and miR-106b, is overexpressed in numerous types of cancer including gastric cancer, hepatocellular carcinoma, esophageal adenocarcinoma, neuroblastoma, and prostate cancer \[[@CR22]--[@CR27]\]. Interestingly, it is located within the 13th intron of MCM7 (Fig. [2](#Fig2){ref-type="fig"}), an oncogene acting in cooperation with the aforementioned cluster in promoting cancer progression \[[@CR27]\].

Fig. 2A schematic representation of the polycistronic miR-106b\~25 cluster and its host gene MCM7, located on chromosome 7q22

The aim of this study was to investigate the expression pattern of miR-106b\~25 cluster and MCM7 in corticotroph adenomas, including CCAs, with regard to their histopathological subtype, other markers of invasiveness, and clinical behavior.

Materials and methods {#Sec2}
=====================

Patient samples {#Sec3}
---------------

A retrospective group of 25 patients diagnosed with Cushing's disease and ACTH-immunopositive pituitary adenoma were enrolled for this study. Tumor samples were retrieved from patients undergoing planned surgery at the Department of Neurosurgery in Military Institute of Medicine in Warsaw. PAs were resected from 5 male and 20 female patients, with a mean age of 47.7 (range 17--78 years) at the time of diagnosis. The detailed clinicopathological characteristics of all patients included in this study are presented in Table [1](#Tab1){ref-type="table"}. Two samples from patients no. three and seven were included: one from a primary and one from a recurrent tumor. All slides were examined by a board-certified pathologist. Tumors were classified according to their size, determined by magnetic resonance imaging (MRI), as microadenomas (\<10 mm) or macroadenomas (\>10 mm). The diagnosis of invasive PAs was based on preoperative MRI assessed using Knosp grading scale combined with intraoperative evaluation \[[@CR28], [@CR29]\]. The diagnosis of CCA, SG-ACTH and DG-ACTH was based on examination of PAs using light and electron microscopy. After surgery, patients were followed-up through MRI and biochemical tests, receiving appropriate medical intervention, including additional surgery or drug therapy in case of tumor recurrence or progression. The follow-up results were defined according to the criteria used by Righi et al. \[[@CR30]\]. Recurrence was defined as radiological evidence of disease relapse in patients without residual tumor after surgical therapy, and progression was defined as tumor regrowth based on MRI and/or evidence of increased plasma hormone levels in patients with residual tumor. A local ethics committee approved all aspects of this study in accordance with the Helsinki Declaration.

Table 1The clinicopathological characteristics of the patients included in this studySample IDSexAgeTumor typeKNOSP gradeTumor dimensionImmunohistochemistry (% of stained cells)Detailed pathological descriptionTP53MIB1MGMTMCM71F33Crooke's cell adenoma0Microadenoma137520 focally: 50Crooke's cell variant, atypical2M49Crooke's cell adenoma4Macroadenoma11050Crooke's cell variant3aF55Crooke's cell adenoma4Macroadenoma33030Crooke's cell variant, atypical3bF56Crooke's cell adenoma4Macroadenoma10101040Crooke's cell variant, atypical4F33Crooke's cell adenoma0Microadenoma339020 focally: 80Crooke's cell variant, atypical5F74Invasive PA3Macroadenoma139020SG-ACTH, atypical, single mitotic figures6F48Invasive PA3Macroadenoma03N/A10DG-ACTH7aM55Invasive PA3MacroadenomaN/AN/AN/AN/ASG-ACTH7bM55Invasive PA3Macroadenoma5020030SG-ACTH, atypical8F59Invasive PA2Macroadenoma03010SG-ACTH9F36Invasive PA4Macroadenoma2207040 focally: 60DG-ACTH, atypical10F66Invasive PA4Macroadenoma255050SG-ACTH, atypical11M61Invasive PA4Macroadenoma2552030SG-ACTH, atypical, nuclear atypia12F17Invasive PA3Macroadenoma339010SG-ACTH, high nuclear atypia13F78Invasive PA4Macroadenoma11905 focally: 30DG-ACTH14F58Invasive PA2Macroadenoma0310050DG-ACTH, atypical15F43Invasive PA2Macroadenoma1310020DG-ACTH, atypical16F44Invasive PA2Microadenoma133015DG-ACTH17F58Noninvasive PA1Macroadenoma1 focally: 201901 focally: 20--18M49Noninvasive PA0Microadenoma01505DG-ACTH19F21Noninvasive PA0Microadenoma1305--20F51Noninvasive PA0Microadenoma11901SG-ACTH, alpha(+/−)21F42Noninvasive PA0Microadenoma117020 focally: 80DG-ACTH22F36Noninvasive PA0Microadenoma01501DG-ACTH23F44Noninvasive PA1Microadenoma111003DG-ACTH24F34Noninvasive PA0Microadenoma20390N/ADG-ACTH, atypical25M34Noninvasive PA1Macroadenoma235030DG-ACTH

Immunohistochemistry (IHC) {#Sec4}
--------------------------

Tissue specimens were fixed in 10% buffered formalin, embedded in paraffin and routinely stained with hematoxylin and eosin. Immunohistochemical staining was performed on paraffin-embedded sections according to the labeled EnVision Flex Visualization System (Dako) with DAB (3,3′-diaminobenzidine) as chromogen, using antibodies against: growth hormone (GH, dilution 1:500), prolactin (PRL, 1:200), ACTH (1:500), β-TSH (1:200), β-FSH (1:500), β-LH (1:500), MGMT (MT 23.2 clone; 1:100)---all antibodies from Thermo Fisher Scientific; the glycoprotein α-subunit (dilution 1:100) from Bio-Rad, UK; TP53 and Ki-67 (MIB-1 clone, ready to use) from Dako, and MCM7 (141.2 clone; 1:200) from Santa Cruz Biotechnology.

Electron microscopy {#Sec5}
-------------------

Small pieces of each tumor were fixed in 2.5% glutaraldehyde, postfixed in 1% osmium tetroxide, dehydrated and embedded in Epon. Ultrathin sections counterstained with uranyl acetate and lead citrate were examined with a Philips CM120 BioTWIN electron microscope.

RNA isolation {#Sec6}
-------------

Total RNA was isolated from FFPE (formalin-fixed paraffin-embedded) tissue blocks as previously described \[[@CR31]\] using the RecoverALL Total Nucleic Acid Isolation Kit for FFPE (Thermo Fisher Scientific). Approximately 15 mg of unsectioned core samples were cut out from the paraffin block and crushed on dry ice. Subsequently, samples were deparaffinized using a series of xylene and ethanol washes, digested with protease and DNase, and eluted with 60 µl of Elution Solution. The quantity and purity of isolated RNA were assessed by the absorbance measurements at wavelengths of 260 and 280 nm on NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific) using 1 µl of RNA. We assumed that samples with OD 260/280 ratios between 1.8 and 2.1 were acceptable for further analysis.

Reverse transcription (RT) and quantitative polymerase chain reaction (qPCR) {#Sec7}
----------------------------------------------------------------------------

MicroRNA expression levels were determined using TaqMan Advanced miRNA Assays (Thermo Fisher Scientific) according to the manufacturer's protocol. The following miRNA assays were used: hsa-miR-25-3p (assay ID: 477994), hsa-miR-93-3p (assay ID: 478209), hsa-miR-93-5p (assay ID: 478210) and hsa-miR-106b-5p (assay ID: 478412). 2--10 ng of RNA isolated from each FFPE sample was reverse transcribed using TaqMan Advanced miRNA cDNA Synthesis Kit (Thermo Fisher Scientific). The subsequent qPCR reactions were performed in a total volume of 10 µl. Each qPCR reaction consisted of: 0.5 µl of TaqMan miRNA Advanced Assay, 5 µl of TaqMan Fast Advanced Mastermix, 2 µl of H~2~O and 2.5 µl of cDNA (diluted 1:10 with H~2~O). Expression levels of U6 snRNA (Assay ID: 001973) were determined using TaqMan MicroRNA Assay (Thermo Fisher Scientific). Reverse transcription reactions in a total volume of 15 µl were performed with miRNA-specific stem-loop RT primer using TaqMan MicroRNA Reverse Transcription Kit (Thermo Fisher Scientific), followed by qPCR reactions in a total volume of 10 µl. Each qPCR reaction consisted of 0.5 µl of U6 TaqMan Assay, 5 µl of TaqMan Universal PCR Master Mix II no UNG (Thermo Fisher Scientific), 0.67 µl of cDNA (diluted 1:10 with H~2~O) and 3.83 µl of H~2~O.

All qPCRs were performed in MicroAmp Fast Optical 96 Well Reaction Plates (Thermo Fisher Scientific) using Applied Biosystems 7500 Fast Real-Time PCR System with 7500 Software V2.0.6 (Thermo Fisher Scientific). Samples were assayed in triplicates, and the obtained CT values for target genes and housekeeping control (U6) were used to calculate relative gene expression using the 2^−ΔCT^ method as described previously \[[@CR32]\].

Statistical analyses {#Sec8}
--------------------

Mann--Whitney and Kruskal--Wallis tests were applied to assess mean differences between groups. To determine the statistical dependence between miRNA expression and clinicopathological characteristics Spearman's or Pearson correlation coefficients were used when appropriate. The area under the receiver operating characteristic curve (AUC) was used to assess the sensitivity and specificity of the biomarkers. Logistic regression was applied to obtain a combined biomarker expression score. Logistic regression and ROC curve analysis were performed in SPSS 18.0 software (SPSS Inc.). All the other statistical tests were performed using GraphPad Prism 6 (GraphPad Software Inc.). All values are presented as mean ± SEM unless indicated otherwise. A p-value of \<0.05 was considered statistically significant.

Results {#Sec9}
=======

Invasive ACTHomas exhibit elevated Ki-67 and MCM7 labeling indices {#Sec10}
------------------------------------------------------------------

We evaluated the expression of Ki-67, MCM7, TP53 and MGMT and sought associations with the clinicopathological characteristics of PA patients: age, tumor size, tumor invasiveness and the histological variant of the tumor (Table [2](#Tab2){ref-type="table"}). The overall mean LIs (%) were: 20.64 ± 3.23 (MCM7), 4.12 ± 0.99 (Ki-67), 5.04 ± 2.15 (TP53), 56.2 ± 7.59 (MGMT). Ki-67 LI correlated significantly with MCM7 LI (Pearson r = 0.4316, p = 0.0312) and TP53 LI (Pearson r = 0.6144, p = 0.0008). No other marker pairs detected by IHC showed a significant correlation between them. Macroadenomas exhibited a higher LI of MCM7 (p = 0.0102) and Ki-67 (p = 0.0435) than microadenomas. Both markers were also more abundantly expressed in invasive PAs comparing to noninvasive tumors (p = 0.0065 and p = 0.0098, respectively). MCM7 LI and Ki-67 LI were similar in CCAs and non-Crooke invasive PAs, albeit significantly higher than in noninvasive tumors (Fig. [3](#Fig3){ref-type="fig"}). Neither MGMT LI nor TP53 LI showed any correlation with the clinicopathological data considered.

Table 2Immunohistochemical staining of TP53, Ki-67, MGMT and MCM7 according to the clinicopathological characteristics of the patientsVariablesnTP53 LI (%)PKi-67 LI (%)PMGMT LI (%)PMCM7 LI (%)PAge \<50152.47 ± 1.280.45483.47 ± 1.210.285661.79 ± 8.980.575517.79 ± 3.820.4225 \>50128.55 ± 4.715.0 ± 1.6949.09 ± 13.1024.27 ± 5.52Tumor dimension Macroadenoma176.38 ± 2.90.34115.438 ± 1.520.043550.67 ± 10.780.532526.63 ± 4.130.0102 Microadenoma103.3 ± 1.922.0 ± 0.3364.50 ± 10.0710.0 ± 2.85Invasiveness of the tumor Invasive PA166.67 ± 3.510.48625.73 ± 1.590.009846.43 ± 11.220.275527.33 ± 4.110.0065 Noninvasive PA112.82 ± 1.741.91 ± 0.3168.64 ± 8.8410.60 ± 3.40Tumor subtype CCA53.6 ± 1.660.12504.00 ± 1.550.234335.00 ± 19.620.157832.00 ± 5.830.2228 DG-ACTH122.42 ± 1.613.58 ± 1.5272.73 ± 7.5218.09 ± 4.85 SG-ACTH811.71 ± 7.25.71 ± 2.4448.57 ± 15.9521.57 ± 6.26Data is presented as % of stained cells (mean ± SEM). P values were calculated using the Kruskal--Wallis or Mann--Whitney tests

Fig. 3Immunohistochemical analysis of MCM7 expression in ACTH-producing pituitary adenoma samples. Presented are representative cases of MCM7-stained Crooke's cell (**a**---2, **b**---3b), invasive (**c**---6, **d**---7a) and noninvasive (**e**---20, **f**---22) PAs. MCM7 (**g**) and Ki-67 (**h**) LIs are presented as % of positively stained cells in examined PAs. Columns represent means ± SEM. The subgroups were compared using the two-sided Mann--Whitney test: \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001

MiR-106b\~25 is upregulated in invasive ACTH-producing PAs {#Sec11}
----------------------------------------------------------

We analyzed the expression pattern of four miRNAs belonging to the miR-106b\~25 cluster in invasive and noninvasive PAs. Since the most prominent changes were observed in CCAs, we separated them into a third subgroup for the following statistical analysis. The expression levels of all four miRNAs were significantly higher in CCAs than in invasive PAs (Fig. [4](#Fig4){ref-type="fig"}a--d). Although all miRNAs showed a general tendency towards a higher expression in invasive in comparison to noninvasive PAs, only the difference in miR-93-5p levels reached statistical significance. We also observed a strong reciprocal correlation between the expression of all miRNAs from the miR-106b\~25 cluster (Fig. [4](#Fig4){ref-type="fig"}e).

Fig. 4The elements of the miR-106b\~25 cluster are coexpressed and upregulated in Crooke's cell and invasive adenomas. **a**--**d** The expression of miR-106b\~25 cluster elements in three subgroups of PAs was compared using the two-sided Mann--Whitney test: \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001. **e** The table presents Pearson correlation coefficients between the expression levels of microRNAs studied. All miRNAs are significantly coexpressed in PAs (p \< 0.0001 for all coefficients)

MCM7 LI correlates with the expression of miR-106b\~25 and tumor's Knosp grade {#Sec12}
------------------------------------------------------------------------------

Since both miR-106b\~25 and MCM7 share the same genomic location and were found to be overexpressed in invasive PAs, we analyzed the relationship between MCM7 LI and individual miRNA expression levels (Fig. [5](#Fig5){ref-type="fig"}). Among the four tested pairs, miR-106b-5p and miR-93-3p levels displayed a significant positive correlation with MCM7 LI (r = 0.4875, p = 0.0135 and r = 0.4033, p = 0.0456, respectively). Interestingly, Spearman's test revealed that the invasiveness of the tumors measured using Knosp grading scale correlates with MCM7 LI as well as miR-106b-5p levels (r = 0.5851, p = 0.0021 and r = 0.4225, p = 0.0281, respectively). The rest of miRNAs from the miR-106b-25\~cluster exhibited similar trends, however they did not reach statistical significance (Fig. [6](#Fig6){ref-type="fig"}).

Fig. 5MCM7 and miR-106b-5p are coexpressed in ACTHomas. **a**--**d** The correlation was calculated using Pearson's coefficient

Fig. 6The expression of miR-106b-5p and MCM7 LI correlates with tumor's Knosp grade. *Scatter plots* showing the relationship between tumor's Knosp grade and miR-106b\~25 expression (**a**--**d**) as well as MCM7 LI (**e**). Correlation was characterized by calculating Spearman's rank coefficient

Combined MCM7 LI and miR-106b\~25 expression differentiates invasive from noninvasive tumors {#Sec13}
--------------------------------------------------------------------------------------------

We performed a ROC curve analysis in order to determine the potential usefulness of IHC biomarkers and microRNA expression levels in discriminating invasive from noninvasive PAs (Fig. [7](#Fig7){ref-type="fig"}). A multivariate ROC that combined the expression of all four miRNAs from the miR-106b\~25 cluster results in a bigger AUC = 0.7841 (95% CI 0.6043--0.9639) than individual miRNAs. Moreover, a combination of the whole miR-106b\~25 cluster expression and MCM7 LI distinguished tumor invasiveness even better, as evidenced by AUC = 0.9133 (95% CI 0.8054--1.000).

Fig. 7MCM7 LI in combination with the expression of miR-106b\~25 is a specific and sensitive test discriminating invasive from noninvasive ACTHomas. **a** In order to establish the role of the IHC biomarkers and microRNAs studied, we analyzed the area under the receiver operating characteristic (AUC ROC). **b** A graphical representation of the three top AUC values

High expression of miR-106b\~25 and MCM7 is associated with unfavorable surgical outcome and distinguishes recurrent and progressive tumors {#Sec14}
-------------------------------------------------------------------------------------------------------------------------------------------

The performed surgical procedures resulted in total tumor resection in 12 (48%) out of 25 patients. During the follow-up period (median time: 27 months, range 6--61), recurrence/progression occurred in 6 (24%) out of 25 patients (median time to relapse: 8 months). Because of the limited number of patients in our study, examined biomarkers were not significantly predictive of relapse risk; however they presented a notable discriminatory ability to predict postoperative tumor recurrence or progression as demonstrated by the ROC AUC analysis (Fig. [8](#Fig8){ref-type="fig"}a). The combination of miR-106b\~25 cluster expression and MCM7 LI was able to accurately (AUC = 0.772; 95% CI 0.5687--0.9751) identify patients with relapse after surgical procedure (Fig. [8](#Fig8){ref-type="fig"}b). Furthermore, the expression of miR-106b\~25 alone (AUC = 0.830; 95% CI 0.6652--0.9941) and in combination with MCM7 (AUC = 0.821; 95% CI 0.6477--0.9933) discriminated patients with post-surgery residual tumor from those that underwent successful radical operation (Fig. [8](#Fig8){ref-type="fig"}a, c). Among residual adenomas, the ones that progressed exhibited significantly higher MCM7 LIs (mean: 36.0 ± 4.0%) than clinically controlled tumors (mean: 16.3 ± 3.9%) (Fig. [8](#Fig8){ref-type="fig"}d).

Fig. 8Performance of MCM7 LI, miR-106b\~25 expression and Ki67 LI in identifying patients with unfavorable prognosis. **a** A summary of AUC ROC calculated for progression/recurrence and post-operative residual tumor accompanied by a graphical representation of those values (**b**,**c**). **d** The expression of MCM7 in residual tumors that progressed or remained stable calculated using the two-sided Mann--Whitney test: \*p \< 0.05

Discussion {#Sec15}
==========

In this study, we demonstrate the expression of the miR-106b\~25 cluster and its host gene MCM7 in a group of ACTH-producing PAs and characterize their utility to evaluate tumor invasiveness and clinical behavior. Our results indicate that both miR-106b\~25 and MCM7 are overexpressed in a group of invasive tumors. Interestingly, the most prominent overexpression of tested biomarkers was observed in Crooke's cell adenomas. To our knowledge, this paper's findings are the first describing miRNA expression in CCAs and co-expression of miR-106b\~25 with MCM7 in pituitary tumors.

Over the last decade, accumulating evidence has proven that deregulation of miRNA expression is involved in PAs development and progression \[[@CR33]--[@CR35]\]. In previous studies utilizing microarrays, many miRNAs were shown to be aberrantly expressed in PAs, and the altered expression of some miRNAs has been associated with tumor diameter, invasiveness, and therapeutic outcome \[[@CR32], [@CR36]\]. Furthermore, it was demonstrated that each PA subtype can be characterized with a specific miRNA expression profile \[[@CR37]\]. Although several miRNAs were demonstrated to be up- or downregulated in ACTH-immunopositive PAs in comparison to normal pituitary tissue \[[@CR37]--[@CR41]\], our current understanding of the biological effects of altered miRNA expression is still limited.

The results of our study are consistent with previous reports demonstrating an important proto-oncogenic role of miR-106b\~25 in tumorigenesis and its overexpression in numerous human malignancies \[[@CR23], [@CR24], [@CR26], [@CR42]\]. Similarly, an upregulation of miR-106b has been recently described in a study that included 55 human pituitary adenomas with different hormonal activities \[[@CR42]\]. Its levels associated with PTEN (phosphatase and tensin homolog) downregulation and the authors suggested that miR-106b-5p targeted PTEN's mRNA and promoted tumor invasiveness mediated via activation of PI3K/Akt signaling. Another group of authors reported a case of nonfunctioning pituitary carcinoma with overexpressed miR-106b-5p when compared to the primary tumor \[[@CR43]\]. Among other miRNAs reported to negatively regulate PTEN expression in pituitary tumors were: miR-17-5p, miR-20a, miR-26b, miR-21 and miR-200c \[[@CR44]--[@CR46]\]. Palumbo et al. \[[@CR47]\] found that inhibition of miR-26b and overexpression of miR-128 resulted in the upregulation of PTEN and decreased PI3K-Akt signaling activity, leading to a suppression of the colony formation ability and invasiveness of pituitary tumor cells. In prostate cancer miR-106b-5p, miR-93-5p and miR-25-3p were confirmed as potent regulators of PTEN, and acting in cooperation with MCM7 they were able to initiate prostate oncogenesis \[[@CR26]\]. Low PTEN expression and high Akt kinase activity are one of the major oncogenic phenomena driving pituitary neoplasia \[[@CR48], [@CR49]\]. These observations, together with the results presented in our study, suggest an involvement of PTEN-targeting miR-106b\~25 in the development and progression of pituitary tumors.

Global miRNA profiling of nonfunctioning pituitary adenomas (NFPAs) and normal pituitary has revealed an overexpression of miR-93-5p in tumor tissues \[[@CR50]\]. In the same study the authors proposed that the miRNA expression profile observed in NFPAs was associated with inhibition of the TGF-β pathway. Interestingly, miRNAs belonging to the miR-106b\~25 cluster were shown to play and important role in the regulation of TGF-β signaling. They were able to inhibit the growth-suppressive functions of this pathway through the repression of downstream mediators p21 and Bim in gastric cancer cells \[[@CR22]\]. In another study it has been shown that miR-106b\~25 targeted Smad7, activated TGF-β and was responsible for its switch from a suppressive to a pro-tumoral character \[[@CR51]\]. In our study we decided to analyze miR-93-3p, a relatively unknown, uncanonical member of miR-106b\~25, of an uncertain significance in oncogenesis. It was postulated to be a tumor suppressor \[[@CR52], [@CR53]\], however Wang et al. found that it is present in sera of patients with late-stage non-small cell lung cancer and is a predictor of poor survival \[[@CR54], [@CR55]\]. Interestingly, the authors underlined a possible interaction of miR-93-3p with Smad7, basing their prediction on bioinformatic analysis.

MCM7, the host gene of the miR-106b\~25 cluster, is a member of minichromosome maintenance family of DNA-binding proteins. It forms a heterohexamer that is a key component of the prereplication complex assembly at the replication origin during early G1 phase \[[@CR56]\]. MCM proteins are physiologically detected only in replicating cells, and are considered as reliable markers of proliferation. As MCM7 is essential for DNA replication, its abnormally high expression was detected in several different types of cancer \[[@CR57]--[@CR59]\]. High MCM7 protein levels were demonstrated to correlate with prostate cancer progression, poor prognosis of non-small cell lung cancer patients, recurrence of colorectal cancer, as well as distant metastases, high histological grade and poor prognosis is soft tissue sarcomas \[[@CR58]--[@CR62]\]. Examination of MCM7 expression pattern in a series of PAs revealed its significantly higher levels in invasive ACTH-producing adenomas, compared to noninvasive tumors \[[@CR18]\]. In the same set of PAs, no significant difference was detected in Ki-67 levels between the invasive and the noninvasive group. Furthermore, high MCM7 levels, but neither TP53 nor Ki-67, were directly associated with risk of recurrence and progression. The findings correspond to the results of our study, in which MCM7 LI was the most accurate IHC biomarker in discrimination between invasive and noninvasive corticotroph tumors.

Similar expression patterns of miR-106b\~25 and MCM7 demonstrated in this study suggest that these genes may be regulated in a similar fashion. Their co-transcription occurs during mitotic cell division \[[@CR63]\], and is under control of a promoter with multiple binding sites for c-Myc and E2F1 \[[@CR64], [@CR65]\], two well-known drivers of pituitary oncogenesis \[[@CR66], [@CR67]\]. It is worth noting that the expression levels of MCM7 and its intronic miRNAs are not perfectly correlated. Several studies have recently reported that their uncoupling can be caused by independent transcription of pri-miRNA using an alternative promoter \[[@CR68], [@CR69]\], as well as nonsense-mediated decay of one of MCM7 transcript variants \[[@CR63]\]. These findings warrant further investigation utilizing mRNA samples, since the protein levels of MCM7 could also be regulated post-transcriptionally \[[@CR70]\].

CCAs are a unique subtype of corticotroph adenomas in terms of pathology and clinical course. They are usually invasive, may exhibit aggressive clinical behavior, and often recur with a low success of cure after reoperation and/or radiotherapy \[[@CR12]\]. Their incidence is estimated at less than 1% of all pituitary adenomas and up to date only about 80 cases of CCAs have been published in the literature \[[@CR12], [@CR71]\]. Although recent ultrastructural and histological findings have made identification of CCAs more conceivable, still little is known about the mechanism underlying the development of these rare adenomas \[[@CR12]\]. The higher expression of miR-106b\~25 in CCAs compared to other groups of ACTHomas suggests that this cluster of oncogenic miRNAs might contribute to the aggressive behavior of these tumors.

In conclusion, our findings demonstrate for the first time that both MCM7 and miRNAs within the miR-106b\~25 cluster (miR-25-3p, miR-93-3p, miR-93-5p and miR-106b-5p) are co-expressed in pituitary tumors and are associated with their invasive character as well as unfavorable outcome after resection. However, due to the limited number of patients included in this study and its retrospective character, further investigations on larger cohorts of patients are needed to validate the diagnostic and prognostic potential of miR-106b\~25 and MCM7 in ACTHomas and other pituitary tumor subtypes. A better understanding of miRNA-mediated regulatory networks constitutes a first step toward the identification of reliable biomarkers and development of novel therapeutic strategies, including miRNA-based therapies, for the treatment of pituitary tumors \[[@CR34], [@CR72]\].
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